Oncotelic Therapeutics (OTCQB: OTLC) has agreed to sell to Mosaic ImmunoEngineering (OTCPK: CPMV) rights to its clinical-stage necroptosis cancer therapies.
The firm’s therapeutics work by disrupting tumor blood flow, a mechanism which can ultimately result in an anti-cancer immune response.
Mosaic said that it expects to initially apply the technology in areas with high unmet medical need, including uveal melanoma and retinoblastoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze